The AHA filed its comment letter on the Department of Health and Human Services’ proposed remedy for the unlawful payment cuts to certain hospitals that participate in the 340B Drug Pricing Program following the Supreme Court’s unanimous decision in American Hospital Association v. Becerra. 

The AHA strongly supported HHS’ proposal to make a one-time lump-sum repayment to hospitals for the amounts they were underpaid from 2018 to 2022, as well the proposal to pay 340B hospitals what they would have received in beneficiary cost-sharing had the unlawful 340B payment policy not been in effect. It urged HHS to finalize these aspects of the proposal immediately.    

At the same time, the AHA pressed HHS not to finalize its proposal to recoup funds from hospitals as a “budget neutrality adjustment.” The AHA explained that HHS’ legal and public policy justifications for this proposed recoupment were groundless and, in reality, the agency has “both the legal obligation and legal flexibility to not seek a clawback of funds that hospitals received as a result of HHS’ own mistakes and have long since spent on patient care.” 

Specifically, the AHA stated HHS should not pursue any budget neutrality adjustment. If HHS does, AHA said the department should: 

•    drastically reduce the overall amount; 
•    delay any recoupment until 2026 or later; 
•    finalize the current aspect of the proposal that would spread the “adjustment” across 16 years; and 
•    recoup funds in a way that does not lead to a Medicare Advantage Organization windfall at the expense of hospitals and health systems.

Comments on the proposed rule are due Sept. 5. 
 

Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…